To compare patient persistence of fingolimod with other disease modifying therapies in patients with relapsing remitting multiple sclerosis in Australia

Trial Profile

To compare patient persistence of fingolimod with other disease modifying therapies in patients with relapsing remitting multiple sclerosis in Australia

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2017 New trial record
    • 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top